Exploiting the Body's Immune System to Treat a Broad Range of Diseases

Read more

ARMO in the News


ARMO BioSciences’s Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC  Read more


ARMO BioSciences Raises $67 Million in a Series C-1 Financing  Read more